Quantcast
Last updated on April 17, 2014 at 16:09 EDT

Latest KaloBios Pharmaceuticals Inc. Stories

2014-04-03 20:22:32

SOUTH SAN FRANCISCO, Calif., April 3, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference: -- 13(th) Annual Needham Healthcare Conference Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City, NY 11:20AM - 11:50AM US ET (8:20AM - 8:50AM US PT) Presentations will include overviews of the company's KB001-A development program to...

2014-03-13 16:28:03

SOUTH SAN FRANCISCO, Calif., March 13, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013. Fiscal 2013 Accomplishments Key corporate accomplishments during fiscal 2013 included: -- KB001-A - Received orphan drug status for KB001-A from the U.S. Food and Drug Administration and the European Medicines Agency...

2014-03-10 16:32:54

BioCentury Conference Presentation to be Webcast SOUTH SAN FRANCISCO, Calif., March 10, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences: -- 26(th) Annual ROTH ConferenceWednesday, March 12, 2014 in Laguna Niguel, California8:00 - 8:30 AM Pacific Time -- BioCentury's Future Leaders in the Biotech Industry ConferenceFriday, March 28, 2014 in New...

2014-02-11 08:32:20

-- Study Focused on Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Who are EphA3 Positive -- SOUTH SAN FRANCISCO, Calif., Feb. 11, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company's anti-EphA3 Humaneered(®) monoclonal antibody (mAb). The company is targeting enrollment of 30 patients for this portion of the Phase 2...

2014-02-05 20:26:52

SOUTH SAN FRANCISCO, Calif., Feb. 5, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David Pritchard, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences: -- 16(th) Annual BIO CEO & Investor ConferenceTuesday, February 11, 2014 in New York City8:30 AM Eastern Time (5:30 AM Pacific Time) -- Leerink Global Healthcare Conference 2014Thursday, February 13, 2014 in New...

2014-01-29 16:28:39

Study Does Not Meet Primary Endpoint SOUTH SAN FRANCISCO, Calif., Jan. 29, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the completion of the randomized, double-blind placebo-controlled Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody (mAb), in patients with severe asthma. While the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV(1) (a measurement of pulmonary...

2014-01-13 08:28:07

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the presentation of epidemiological research sponsored by Sanofi Pasteur, KaloBios' exclusive licensee for KB001-A, estimating the incidence of Pseudomonas aeruginosa Ventilator Associated Pneumonia (Pa-VAP) in at-risk patients requiring intubation and mechanical ventilation. The presentation also describes the risk factors among patients with VAP and Pa-VAP. The new...

2014-01-07 08:31:00

Lam Joins KaloBios with Over 28 Years Biopharmaceutical Manufacturing Experience SOUTH SAN FRANCISCO, Calif., Jan. 7, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Harry Lam, Ph.D. as Head of Manufacturing. Dr. Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech, where he ultimately served as Global Head of Contract Manufacturing Operations, Commercial Drug...

2013-12-10 08:31:29

- Data Presented as Poster at American Society of Hematology Annual Meeting and Exhibition SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been...

2013-12-05 16:25:31

- KB004, experimental anti-EphA3 monoclonal antibody therapeutic, in clinical development against hematologic cancers SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition of matter patent covering certain antibodies targeting EphA3, including KaloBios' experimental anti-cancer monoclonal antibody (mAb), KB004. The allowed claims...